SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2007
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
FOR IMMEDIATE RELEASE 26 MARCH 2007 SkyePharma PLC Voting Rights and Capital In conformity with the Transparency Directive, we hereby notify the market of the following: Consequent to the admission to trading of 61,224,490 new Ordinary Shares of 10p each which took place this morning, SkyePharma PLC's issued share capital consists of 814,988,636 Ordinary Shares with voting rights. No shares are held in treasury. Therefore, the total number of voting rights in the Company is 814,988,636. The above figure (814,988,636) may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change in their interest in, SkyePharma PLC under the FSA's Disclosure and Transparency Rules.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
By: /s/ John Murphy
Name: John Murphy
Title: Company Secretary
Date: March 26, 2007